Last reviewed · How we verify

NCT07061054

Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN System

Not yet recruiting NA Last updated 11 February 2026
What this trial tests

NA trial testing Netrod™ six-electrode radiofrequency renal denervation system in Uncontrolled Hypertension in 20 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
1 March 2027
1 December 2027

Quick facts

Lead sponsorShanghai Golden Leaf MedTec Co. Ltd
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 April 2026
Primary completion1 March 2027
Estimated completion1 December 2027
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai Golden Leaf MedTec Co. Ltd

Who can join

Adults 18 to 70, any sex, with Uncontrolled Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-arm, non-randomized, open-label investigation aims to collect safety and efficacy data of the CE-Marked Netrod™ RDN System in treating European patients with primary hypertension in the absence of anti-hypertensive medication.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Uncontrolled Hypertension

Currently open trials in the same condition.

Other Shanghai Golden Leaf MedTec Co. Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07061054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing